SlideShare a Scribd company logo
www.julphar.net
ICH GUIDELINE : Q3C
GUIDELINE FOR RESIDUAL SOLVENTS
www.julphar.net
Contents
• Introduction
• Scope of the Guideline
• Classification
• Limits of Residual Solvents
• Options for Describing Limits of Class 2 Solvents
• Analytical Procedures
• Reporting Levels of residual solvents
• Residual Solvents in Pharmaceuticals
• Glossary
www.julphar.net
Introduction
Residual solvents in Pharmaceuticals are defined in ICH Q3C as organic
volatile chemicals that are used or produced in the manufacture of drug
substances, excipients or in the preparation of drug products. They are not
completely removed by practical manufacturing techniques.
Residual solvents are used in manufacture either to enhance the yield or
determine characteristics of the substances such as crystal form, purity and
solubility. There is no therapeutic benefit from residual solvents.
Since there is no therapeutic benefit from residual solvents, all residual
solvents should be removed to the extent possible to meet product
specifications, good manufacturing practices, or other quality-based
requirements.
www.julphar.net
To recommend acceptable amounts for residual solvents in pharmaceuticals
for the safety of the patient. The guideline recommends use of less toxic
solvents and describes levels considered to be toxicologically acceptable for
some residual solvents.
The guideline applies to all dosage forms and routes of administration.
This guidelines does not address all possible solvents, only those identified in
drugs at that time, neither address solvents intentionally used as excipients
nor solvates.
The maximum acceptable intake per day of residual solvent in
pharmaceutical products is defined as “permitted daily exposure” (PDE)
Previously, another terms were used like “Tolerable daily intake” (TDI) &
“Acceptable daily intake” (ADI) by different organization & authorities, but
now usually this new term “PDE” is used
Scope of the Guideline
www.julphar.net
Classification
Residual Solvents are classified according to
their Risk Assessments to human health to
3 main classes:
Class 1 solvents
Solvents to be
avoided
Class 2 solvents
Solvents to be
limited
Class 3 solvents
Solvents with low
toxic potential
www.julphar.net
ClassificationofResidualSolventsby
RiskAssessment
Class 1 solvents
Solvents to be avoided
Known human carcinogens, strongly
suspected human carcinogens, and
environmental hazards
Class 2 solvents
Solvents to be limited
Non-genotoxic animal carcinogens or possible
causative agents of other irreversible toxicity
such as neurotoxicity or teratogenicity.
Class 3 solvents
Solvents with low
toxic potential
Solvents with low toxic potential to man; no
health-based exposure limit is needed.
www.julphar.net
Limits of Residual Solvents
www.julphar.net
Class 1 Solvents
Solvents to Be Avoided
Solvents in Class 1 should not be employed in the manufacture of drug substances,
excipients, and drug products because of their unacceptable toxicity or their
deleterious environmental effect. However, if their use is unavoidable in order to
produce a drug product with a significant therapeutic advance, then their levels
should be restricted as shown in Table unless otherwise justified.
Solvent
Concentration limit
(ppm)
Concern
Benzene 2 Carcinogen
Carbon tetrachloride 4 Toxic and environmental hazard
1,2-Dichloroethane 5 Toxic
1,1-Dichloroethene 8 Toxic
1,1,1-Trichloroethane 1500 Environmental hazard
www.julphar.net
Solvents to be limited
Solvents in class 2 should be limited in pharmaceutical products because of their
inherent toxicity. Examples of class 2 solvent in the below table.
Class 2 Solvents
Solvent PDE (mg/day)
Concentration limit
(ppm)
Acetonitrile 4.1 410
Chloroform 0.6 60
Cyclohexane 38.8 3880
Formamide 2.2 220
Methanol 30 3000
N-Methylpyrrolidone 5.3 530
Tetrahydrofuran 7.2 720
Xylene 21.7 2170
Toluene 8.9 890
www.julphar.net
Class 3 Solvents (Solvents with low toxic potential)
•Solvents in Class 3 may be regarded as lower risk to human health. However,
there are no long-term toxicity or carcinogenicity studies for many of the
solvents in Class 3.
•These solvents are considered of no human health hazard
•Available data indicate that they are less toxic in acute or short-term studies
and negative in genotoxicity studies.
• It is considered that amounts of these residual solvents of 50 mg per day or
less (corresponding to 5000 ppm or 0.5% under Option 1) would be
acceptable without justification.
• Higher amounts may also be acceptable provided they are realistic in relation
to manufacturing capability and GMP.
www.julphar.net
Class 3 Solvents (Continue)
Acetone Methylisobutyl ketone Ethyl ether
Acetic acid Heptane Dimethyl sulfoxide Ethyl formate
Anisole Ethanol Formic acid
Methyl acetate Ethyl acetate 3-Methyl-1-butanol
Butyl acetate tert-Butylmethyl ether Isobutyl acetate
1-Butanol Methylethyl ketone 1-Pentanol
2-Methyl-1-propanol Heptane Isopropyl acetate
2-Butanol Pentane 1-Propanol
Examples of Class 3 solvents which should be limited by GMP or other quality
based requirements.
www.julphar.net
Solvents for which No Adequate Toxicological Data was Found
•The following solvents may also be of interest to manufacturers of excipients,
drug substances, or drug products. However, no adequate toxicological data on
which to base a PDE was found.
•Manufacturers should supply justification for residual levels of these solvents
in pharmaceutical products.
• Examples :
1,1-Diethoxypropane Methylisopropyl ketone
1,1-Dimethoxymethane Methyltetrahydrofuran
2,2-Dimethoxypropane Petroleum ether
Isooctane Trichloroacetic acid
Isopropyl ether Trifluoroacetic acid
www.julphar.net
Options for Describing Limits of Class 2 Solvents
These options are used to describe the limit of Class 2 solvents.
Testing should be performed for residual solvents when production or
purification processes are known to result in the presence of such solvents.
Option 1:
By assuming a product mass of 10 g administered daily.
Concentration (ppm) = 1000 x PDE / Dose
Here, PDE is given in terms of mg/day and dose is given in g/day.
No further calculation is necessary provided that the daily dose does not
exceed 10 g.
Option 2:
Products that are administered in doses greater than 10 g per day.
Applied by adding the amounts of a residual solvent present in each of the
components of the drug product. The sum of the amounts of solvent per
day should be less than that given by the PDE.
www.julphar.net
Example for Option 2
The permitted daily exposure to acetonitrile is 4.1 mg per day; thus, the
Option 1 limit is 410 ppm. The maximum administered daily mass of a drug
product is 5.0 g, and the drug product contains two excipients. The
composition of the drug product and the calculated maximum content of
residual acetonitrile are given in the following table.
Excipient 1 meets the Option 1 limit, but the drug substance, excipient 2, and
drug product do not meet the Option 1 limit. however, the product meets the
Option 2 limit of 4.1 mg per day and thus conforms to the recommendations in
this guideline.
www.julphar.net
What if the product meets neither the Option 1
nor the Option 2 limit ?
The manufacturer could test the drug product to determine if the formulation
process reduced the level of acetonitrile. If the level of acetonitrile was not
reduced during formulation to the allowed limit, then the manufacturer of
the drug product should take other steps to reduce the amount of acetonitrile
in the drug product. If all of these steps fail to reduce the level of residual
solvent, in exceptional cases the manufacturer could provide a summary of
efforts made to reduce the solvent level to meet the guideline value, and
provide a risk benefit analysis to support allowing the product to be utilized
with residual solvent at a higher level.
www.julphar.net
Specifications for class 1 and class 2 residual
solvents in active substances
A) Class 1 solvents used as starting materials
They should be routinely controlled, either in a suitable intermediate or in
the final active substance.
B) Class 1 solvents present as an impurity
It should be NMT 30 % of the specified limit, in a suitable intermediate or in
the final active substance. Supporting data should be presented on 6
consecutive pilot scale batches or 3 consecutive industrial scale batches.
C) Class 2 solvents used in the last step of the synthesis
It should be routinely controlled in the final active substance.
D) Class 2 solvents used prior to the last step of the synthesis
It should be NMT 10 % of the acceptable concentration limit (e.g.,
acetonitrile 41 ppm). Supporting data should be presented on 6 consecutive
pilot scale batches or 3 consecutive industrial scale batches.
www.julphar.net
Analytical Procedures
•Residual solvents are typically determined using chromatographic techniques
such as gas chromatography.
• Any harmonized procedures for determining levels of residual solvents as
described in the pharmacopoeias should be used.
• Manufacturers would be free to select the most appropriate validated
analytical procedure for a particular application.
• If only Class 3 solvents are present, a nonspecific method such as loss on
drying may be used.
www.julphar.net
Reporting levels of residual solvents
• Manufacturers of pharmaceutical products need certain information about
the content of residual solvents in excipients or drug substances.
• The following statements are given in the ICH Guideline as acceptable
examples of the information that could be provided from a supplier of
excipients or drug substances to a pharmaceutical manufacturer.
 Only Class 3 solvents are likely to be present. Loss on drying is less than 0.5%.
Only Class 2 solvents X, Y, ... are likely to be present. All are below the Option 1
limit.
Only Class 2 solvents X, Y, ... and Class 3 solvents are likely to be present. Residual
Class 2 solvents are below the Option 1 limit and residual Class 3 solvents are below
0.5%.
www.julphar.net
• If Class 1 solvents are likely to be present, they should be identified and
quantified.
• If solvents of Class 2 or Class 3 are present at greater than their Option 1 limits or
0.5%, respectively, they should be identified and quantified.
• Manufacturer could provide a summary of efforts made to reduce the solvent
level to meet the guideline value and provide a risk-benefit analysis to support
allowing the product to be utilized with residual solvent at a higher level.
• Higher levels of residual solvents may be acceptable in certain cases such as short
term (30 days or less) or topical application. Justification for these levels should be
made on a case by case basis.
Example for Residual Solvents Declaration
Reporting levels of residual solvents
www.julphar.net
Residual Solvents in Pharmaceuticals
Exposure limits in this guideline are established by referring to
methodologies and toxicity data described in EHC and IRIS* monographs.
However, some specific assumptions about residual solvents to be used
in the synthesis and formulation of pharmaceutical products should be
taken into account in establishing exposure limits:
1) Patients (not the general population) use pharmaceuticals to treat their
diseases or for prophylaxis to prevent infection or disease.
2) Residual solvents are unavoidable components in pharmaceutical
production and will often be a part of drug products.
3) Residual solvents should not exceed recommended levels except in
exceptional circumstances.
EHC: Environmental Health Criteria
IRIS: Integrated Risk Information System
www.julphar.net
4) Data from toxicological studies that are used to determine acceptable
levels for residual solvents should have been generated using appropriate
protocols such as those described for example by FDA Red Book and EPA*.
FDA Red Book: Toxicological Principles for the Safety Assessment of Direct Food Additives and Color
Additives Used in Food
EPA: US Environmental Protection Agency
References:
Impurities: Guideline for Residual Solvents Q3C(R5)
EMA: CVMP/VICH/502/99 Guideline on impurities: residual solvents , Annex I: specifications for
class 1 and class 2 residual solvents in active substances
www.julphar.net
Glossary
Term Meaning Term Meaning
ICH
INTERNATIONAL CONFERENCE
ON HARMONISATION
LOEL Lowest-Observed Effect Level
WHO World Health Organization NOEL No-Observed Effect Level
GMP Good Manufacturing Practice PDE Permitted Daily Exposure
EHC Environmental Health Criteria TDI Tolerable Daily Intake
IRIS
Integrated Risk Information
System
ADI Acceptable Daily Intake
IPCS
International Program on
Chemical Safety
USFDA
United States Food and Drug
Administration
USEPA
United States Environmental
Protection Agency
EWG Expert Working Group
www.julphar.net
Thank you

More Related Content

What's hot

Basics of Impurity Profiling
Basics of Impurity ProfilingBasics of Impurity Profiling
Basics of Impurity Profiling
Pankaj Soni
 
Impurities in residual solvents
Impurities in residual solventsImpurities in residual solvents
Impurities in residual solvents
MehulJain143
 
ICH guidelines on impurities in new drug products.pptx
ICH guidelines on impurities in new drug products.pptxICH guidelines on impurities in new drug products.pptx
ICH guidelines on impurities in new drug products.pptx
Divya Pushp
 
ICH- Q3 Impurity
ICH- Q3 ImpurityICH- Q3 Impurity
ICH- Q3 Impurity
NIHASULTANA2
 
Impurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek JainImpurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek Jain
Vivek Jain
 
ICH Q3B (R2):Impurities in new drug products
ICH Q3B (R2):Impurities in new drug products ICH Q3B (R2):Impurities in new drug products
ICH Q3B (R2):Impurities in new drug products
Vinit Gohel
 
Residual solvent
Residual solvent Residual solvent
Residual solvent
Saptarshi Das
 
Validation parameters
Validation parametersValidation parameters
Validation parameters
Sandhya Chintalacheruvu
 
Impurity Profile
Impurity ProfileImpurity Profile
Impurity Profile
NagaJyothiKunduru
 
Q3A(R2) IMPURITIES IN NEW DRUG SUBSTANCES
Q3A(R2)  IMPURITIES IN NEW DRUG SUBSTANCESQ3A(R2)  IMPURITIES IN NEW DRUG SUBSTANCES
Q3A(R2) IMPURITIES IN NEW DRUG SUBSTANCES
Muhamad Abdalkader
 
Ich q3 d elemental impurities
Ich q3 d elemental impuritiesIch q3 d elemental impurities
Ich q3 d elemental impurities
santoshnarla
 
Analytical method validation as per ich and usp
Analytical method validation as per ich and usp Analytical method validation as per ich and usp
Analytical method validation as per ich and usp
shreyas B R
 
IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS
prakash64742
 
Analytical methods validation as per ich & usp
Analytical methods validation as per ich & uspAnalytical methods validation as per ich & usp
Analytical methods validation as per ich & usp
GANESH NIGADE
 
ICH Q2 Analytical Method Validation
ICH Q2  Analytical Method ValidationICH Q2  Analytical Method Validation
ICH Q2 Analytical Method Validation
Naila Kanwal
 
Setting spec limit for imps
Setting spec limit for impsSetting spec limit for imps
Setting spec limit for imps
ICHAPPS
 
Elemental Impurities by Shiv Kalia.pptx
Elemental Impurities by Shiv Kalia.pptxElemental Impurities by Shiv Kalia.pptx
Elemental Impurities by Shiv Kalia.pptx
Shiv Kalia
 
Rationale for the reporting control of degradation products
Rationale for the reporting control of degradation products Rationale for the reporting control of degradation products
Rationale for the reporting control of degradation products
ManiKandan1405
 
Qualification of instrumets
Qualification of instrumetsQualification of instrumets
Qualification of instrumets
ChowdaryPavani
 

What's hot (20)

Basics of Impurity Profiling
Basics of Impurity ProfilingBasics of Impurity Profiling
Basics of Impurity Profiling
 
Impurities in residual solvents
Impurities in residual solventsImpurities in residual solvents
Impurities in residual solvents
 
ICH guidelines on impurities in new drug products.pptx
ICH guidelines on impurities in new drug products.pptxICH guidelines on impurities in new drug products.pptx
ICH guidelines on impurities in new drug products.pptx
 
ICH- Q3 Impurity
ICH- Q3 ImpurityICH- Q3 Impurity
ICH- Q3 Impurity
 
Impurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek JainImpurities ICH Q3 Guidelines Au Vivek Jain
Impurities ICH Q3 Guidelines Au Vivek Jain
 
ICH Q3B (R2):Impurities in new drug products
ICH Q3B (R2):Impurities in new drug products ICH Q3B (R2):Impurities in new drug products
ICH Q3B (R2):Impurities in new drug products
 
Residual solvent
Residual solvent Residual solvent
Residual solvent
 
Validation parameters
Validation parametersValidation parameters
Validation parameters
 
Impurity Profile
Impurity ProfileImpurity Profile
Impurity Profile
 
Q3A(R2) IMPURITIES IN NEW DRUG SUBSTANCES
Q3A(R2)  IMPURITIES IN NEW DRUG SUBSTANCESQ3A(R2)  IMPURITIES IN NEW DRUG SUBSTANCES
Q3A(R2) IMPURITIES IN NEW DRUG SUBSTANCES
 
Ich q3 d elemental impurities
Ich q3 d elemental impuritiesIch q3 d elemental impurities
Ich q3 d elemental impurities
 
Analytical method validation as per ich and usp
Analytical method validation as per ich and usp Analytical method validation as per ich and usp
Analytical method validation as per ich and usp
 
IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS IMPURITIES OF NEW DRUG PRODUCTS
IMPURITIES OF NEW DRUG PRODUCTS
 
Analytical methods validation as per ich & usp
Analytical methods validation as per ich & uspAnalytical methods validation as per ich & usp
Analytical methods validation as per ich & usp
 
ICH Q2 Analytical Method Validation
ICH Q2  Analytical Method ValidationICH Q2  Analytical Method Validation
ICH Q2 Analytical Method Validation
 
Setting spec limit for imps
Setting spec limit for impsSetting spec limit for imps
Setting spec limit for imps
 
Elemental Impurities by Shiv Kalia.pptx
Elemental Impurities by Shiv Kalia.pptxElemental Impurities by Shiv Kalia.pptx
Elemental Impurities by Shiv Kalia.pptx
 
Rationale for the reporting control of degradation products
Rationale for the reporting control of degradation products Rationale for the reporting control of degradation products
Rationale for the reporting control of degradation products
 
Residual Solvent Limit Calculation
Residual Solvent Limit CalculationResidual Solvent Limit Calculation
Residual Solvent Limit Calculation
 
Qualification of instrumets
Qualification of instrumetsQualification of instrumets
Qualification of instrumets
 

Similar to Residual solvents

Residual solvents
Residual solvents Residual solvents
Residual solvents
akunuri nagakrishna
 
ICH Q3C GUIDELINE
ICH Q3C GUIDELINEICH Q3C GUIDELINE
ICH Q3C GUIDELINE
Kalyani722
 
What is Residual solvent and its identification
What is Residual solvent and its identificationWhat is Residual solvent and its identification
What is Residual solvent and its identification
Hasan Al Banna
 
Residual Solvents, USP <467>
Residual Solvents, USP <467>Residual Solvents, USP <467>
Residual Solvents, USP <467>
Aditya Sharma
 
Residual Solvents, Their Limits and PDE A Review
Residual Solvents, Their Limits and PDE A ReviewResidual Solvents, Their Limits and PDE A Review
Residual Solvents, Their Limits and PDE A Review
ijtsrd
 
Indu...impurity profiling of api’s using rp hplc as per
Indu...impurity profiling of api’s using rp hplc as perIndu...impurity profiling of api’s using rp hplc as per
Indu...impurity profiling of api’s using rp hplc as perhdghcfgfgftf
 
Impurities in drug substances and drug products
Impurities in drug substances and drug productsImpurities in drug substances and drug products
Impurities in drug substances and drug products
ShilpaIkhar
 
ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10
BHAGYASHRI BHANAGE
 
Ich guidlines q and s
Ich guidlines  q and sIch guidlines  q and s
Ich guidlines q and s
Bashant Kumar sah
 
Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoi...
Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoi...Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoi...
Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoi...
Shimadzu Scientific Instruments
 
ICH Q3 D
ICH Q3 DICH Q3 D
ICH Q3Impurities
  ICH Q3Impurities  ICH Q3Impurities
ICH Q3Impurities
Madhan Gopal
 
Stephen 205 (1)
Stephen 205 (1)Stephen 205 (1)
Stephen 205 (1)farsiya
 
IPQC Tests for Opthalmic Preparations.pptx
IPQC Tests for Opthalmic Preparations.pptxIPQC Tests for Opthalmic Preparations.pptx
IPQC Tests for Opthalmic Preparations.pptx
SohailSheikh62
 
ICH guidelines
ICH guidelines ICH guidelines
ICH guidelines
Mayur Bodhankar
 
Impurity of drug Subatances.pptx
Impurity of drug Subatances.pptxImpurity of drug Subatances.pptx
Impurity of drug Subatances.pptx
MNSharifMintu1
 
Impurity in Drug Substance & Product
Impurity in Drug Substance & ProductImpurity in Drug Substance & Product
Impurity in Drug Substance & Product
Obaid Ali / Roohi B. Obaid
 
Impurity profiling and degradent characterization {presented by shameer m.pha...
Impurity profiling and degradent characterization {presented by shameer m.pha...Impurity profiling and degradent characterization {presented by shameer m.pha...
Impurity profiling and degradent characterization {presented by shameer m.pha...
ShameerAbid
 
VICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptxVICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptx
ssuser796efb
 

Similar to Residual solvents (20)

Residual solvents
Residual solvents Residual solvents
Residual solvents
 
ICH Q3C GUIDELINE
ICH Q3C GUIDELINEICH Q3C GUIDELINE
ICH Q3C GUIDELINE
 
What is Residual solvent and its identification
What is Residual solvent and its identificationWhat is Residual solvent and its identification
What is Residual solvent and its identification
 
Residual Solvents, USP <467>
Residual Solvents, USP <467>Residual Solvents, USP <467>
Residual Solvents, USP <467>
 
Residual Solvents, Their Limits and PDE A Review
Residual Solvents, Their Limits and PDE A ReviewResidual Solvents, Their Limits and PDE A Review
Residual Solvents, Their Limits and PDE A Review
 
Indu...impurity profiling of api’s using rp hplc as per
Indu...impurity profiling of api’s using rp hplc as perIndu...impurity profiling of api’s using rp hplc as per
Indu...impurity profiling of api’s using rp hplc as per
 
Impurities in drug substances and drug products
Impurities in drug substances and drug productsImpurities in drug substances and drug products
Impurities in drug substances and drug products
 
ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10
 
Ich guidlines q and s
Ich guidlines  q and sIch guidlines  q and s
Ich guidlines q and s
 
Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoi...
Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoi...Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoi...
Cannabis Analyzer for Potency Provides Effortless Determination of Cannabinoi...
 
ICH Q3 D
ICH Q3 DICH Q3 D
ICH Q3 D
 
ICH Q3Impurities
  ICH Q3Impurities  ICH Q3Impurities
ICH Q3Impurities
 
Stephen 205 (1)
Stephen 205 (1)Stephen 205 (1)
Stephen 205 (1)
 
IPQC Tests for Opthalmic Preparations.pptx
IPQC Tests for Opthalmic Preparations.pptxIPQC Tests for Opthalmic Preparations.pptx
IPQC Tests for Opthalmic Preparations.pptx
 
ICH guidelines
ICH guidelines ICH guidelines
ICH guidelines
 
Impurity of drug Subatances.pptx
Impurity of drug Subatances.pptxImpurity of drug Subatances.pptx
Impurity of drug Subatances.pptx
 
Impurity in Drug Substance & Product
Impurity in Drug Substance & ProductImpurity in Drug Substance & Product
Impurity in Drug Substance & Product
 
Impurity profiling and degradent characterization {presented by shameer m.pha...
Impurity profiling and degradent characterization {presented by shameer m.pha...Impurity profiling and degradent characterization {presented by shameer m.pha...
Impurity profiling and degradent characterization {presented by shameer m.pha...
 
VICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptxVICH GL39 Specifications-pharmaceuticals..pptx
VICH GL39 Specifications-pharmaceuticals..pptx
 
Tushar Ceutics
Tushar CeuticsTushar Ceutics
Tushar Ceutics
 

Recently uploaded

Deepfake Detection_Using Machine Learning .pptx
Deepfake Detection_Using Machine Learning .pptxDeepfake Detection_Using Machine Learning .pptx
Deepfake Detection_Using Machine Learning .pptx
mahalsuraj389
 
QA Paediatric dentistry department, Hospital Melaka 2020
QA Paediatric dentistry department, Hospital Melaka 2020QA Paediatric dentistry department, Hospital Melaka 2020
QA Paediatric dentistry department, Hospital Melaka 2020
Azreen Aj
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
The Harvest Clinic
 
Immunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentationImmunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentation
BeshedaWedajo
 
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptxGLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
priyabhojwani1200
 
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
ranishasharma67
 
A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisoners
Ahmed Elmi
 
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
Nguyễn Thị Vân Anh
 
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
aunty1x2
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Dr. David Greene Arizona
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
ranishasharma67
 
Overcome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptxOvercome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptx
renewlifehypnosis
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
o6ov5dqmf
 
Performance Standards for Antimicrobial Susceptibility Testing
Performance Standards for Antimicrobial Susceptibility TestingPerformance Standards for Antimicrobial Susceptibility Testing
Performance Standards for Antimicrobial Susceptibility Testing
Nguyễn Thị Vân Anh
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Guillermo Rivera
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Rommel Luis III Israel
 
How many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdfHow many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdf
pubrica101
 
Introduction to Forensic Pathology course
Introduction to Forensic Pathology courseIntroduction to Forensic Pathology course
Introduction to Forensic Pathology course
fprxsqvnz5
 
What Are Homeopathic Treatments for Migraines.pdf
What Are Homeopathic Treatments for Migraines.pdfWhat Are Homeopathic Treatments for Migraines.pdf
What Are Homeopathic Treatments for Migraines.pdf
Dharma Homoeopathy
 
CANCER CANCER CANCER CANCER CANCER CANCER
CANCER  CANCER  CANCER  CANCER  CANCER CANCERCANCER  CANCER  CANCER  CANCER  CANCER CANCER
CANCER CANCER CANCER CANCER CANCER CANCER
KRISTELLEGAMBOA2
 

Recently uploaded (20)

Deepfake Detection_Using Machine Learning .pptx
Deepfake Detection_Using Machine Learning .pptxDeepfake Detection_Using Machine Learning .pptx
Deepfake Detection_Using Machine Learning .pptx
 
QA Paediatric dentistry department, Hospital Melaka 2020
QA Paediatric dentistry department, Hospital Melaka 2020QA Paediatric dentistry department, Hospital Melaka 2020
QA Paediatric dentistry department, Hospital Melaka 2020
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
 
Immunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentationImmunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentation
 
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptxGLOBAL WARMING BY PRIYA BHOJWANI @..pptx
GLOBAL WARMING BY PRIYA BHOJWANI @..pptx
 
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
💘Ludhiana ℂall Girls 📞]][89011★83002][[ 📱 ❤ESCORTS service in Ludhiana💃💦Ludhi...
 
A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisoners
 
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
 
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
 
Overcome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptxOvercome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptx
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
 
Performance Standards for Antimicrobial Susceptibility Testing
Performance Standards for Antimicrobial Susceptibility TestingPerformance Standards for Antimicrobial Susceptibility Testing
Performance Standards for Antimicrobial Susceptibility Testing
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
 
How many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdfHow many patients does case series should have In comparison to case reports.pdf
How many patients does case series should have In comparison to case reports.pdf
 
Introduction to Forensic Pathology course
Introduction to Forensic Pathology courseIntroduction to Forensic Pathology course
Introduction to Forensic Pathology course
 
What Are Homeopathic Treatments for Migraines.pdf
What Are Homeopathic Treatments for Migraines.pdfWhat Are Homeopathic Treatments for Migraines.pdf
What Are Homeopathic Treatments for Migraines.pdf
 
CANCER CANCER CANCER CANCER CANCER CANCER
CANCER  CANCER  CANCER  CANCER  CANCER CANCERCANCER  CANCER  CANCER  CANCER  CANCER CANCER
CANCER CANCER CANCER CANCER CANCER CANCER
 

Residual solvents

  • 1. www.julphar.net ICH GUIDELINE : Q3C GUIDELINE FOR RESIDUAL SOLVENTS
  • 2. www.julphar.net Contents • Introduction • Scope of the Guideline • Classification • Limits of Residual Solvents • Options for Describing Limits of Class 2 Solvents • Analytical Procedures • Reporting Levels of residual solvents • Residual Solvents in Pharmaceuticals • Glossary
  • 3. www.julphar.net Introduction Residual solvents in Pharmaceuticals are defined in ICH Q3C as organic volatile chemicals that are used or produced in the manufacture of drug substances, excipients or in the preparation of drug products. They are not completely removed by practical manufacturing techniques. Residual solvents are used in manufacture either to enhance the yield or determine characteristics of the substances such as crystal form, purity and solubility. There is no therapeutic benefit from residual solvents. Since there is no therapeutic benefit from residual solvents, all residual solvents should be removed to the extent possible to meet product specifications, good manufacturing practices, or other quality-based requirements.
  • 4. www.julphar.net To recommend acceptable amounts for residual solvents in pharmaceuticals for the safety of the patient. The guideline recommends use of less toxic solvents and describes levels considered to be toxicologically acceptable for some residual solvents. The guideline applies to all dosage forms and routes of administration. This guidelines does not address all possible solvents, only those identified in drugs at that time, neither address solvents intentionally used as excipients nor solvates. The maximum acceptable intake per day of residual solvent in pharmaceutical products is defined as “permitted daily exposure” (PDE) Previously, another terms were used like “Tolerable daily intake” (TDI) & “Acceptable daily intake” (ADI) by different organization & authorities, but now usually this new term “PDE” is used Scope of the Guideline
  • 5. www.julphar.net Classification Residual Solvents are classified according to their Risk Assessments to human health to 3 main classes: Class 1 solvents Solvents to be avoided Class 2 solvents Solvents to be limited Class 3 solvents Solvents with low toxic potential
  • 6. www.julphar.net ClassificationofResidualSolventsby RiskAssessment Class 1 solvents Solvents to be avoided Known human carcinogens, strongly suspected human carcinogens, and environmental hazards Class 2 solvents Solvents to be limited Non-genotoxic animal carcinogens or possible causative agents of other irreversible toxicity such as neurotoxicity or teratogenicity. Class 3 solvents Solvents with low toxic potential Solvents with low toxic potential to man; no health-based exposure limit is needed.
  • 8. www.julphar.net Class 1 Solvents Solvents to Be Avoided Solvents in Class 1 should not be employed in the manufacture of drug substances, excipients, and drug products because of their unacceptable toxicity or their deleterious environmental effect. However, if their use is unavoidable in order to produce a drug product with a significant therapeutic advance, then their levels should be restricted as shown in Table unless otherwise justified. Solvent Concentration limit (ppm) Concern Benzene 2 Carcinogen Carbon tetrachloride 4 Toxic and environmental hazard 1,2-Dichloroethane 5 Toxic 1,1-Dichloroethene 8 Toxic 1,1,1-Trichloroethane 1500 Environmental hazard
  • 9. www.julphar.net Solvents to be limited Solvents in class 2 should be limited in pharmaceutical products because of their inherent toxicity. Examples of class 2 solvent in the below table. Class 2 Solvents Solvent PDE (mg/day) Concentration limit (ppm) Acetonitrile 4.1 410 Chloroform 0.6 60 Cyclohexane 38.8 3880 Formamide 2.2 220 Methanol 30 3000 N-Methylpyrrolidone 5.3 530 Tetrahydrofuran 7.2 720 Xylene 21.7 2170 Toluene 8.9 890
  • 10. www.julphar.net Class 3 Solvents (Solvents with low toxic potential) •Solvents in Class 3 may be regarded as lower risk to human health. However, there are no long-term toxicity or carcinogenicity studies for many of the solvents in Class 3. •These solvents are considered of no human health hazard •Available data indicate that they are less toxic in acute or short-term studies and negative in genotoxicity studies. • It is considered that amounts of these residual solvents of 50 mg per day or less (corresponding to 5000 ppm or 0.5% under Option 1) would be acceptable without justification. • Higher amounts may also be acceptable provided they are realistic in relation to manufacturing capability and GMP.
  • 11. www.julphar.net Class 3 Solvents (Continue) Acetone Methylisobutyl ketone Ethyl ether Acetic acid Heptane Dimethyl sulfoxide Ethyl formate Anisole Ethanol Formic acid Methyl acetate Ethyl acetate 3-Methyl-1-butanol Butyl acetate tert-Butylmethyl ether Isobutyl acetate 1-Butanol Methylethyl ketone 1-Pentanol 2-Methyl-1-propanol Heptane Isopropyl acetate 2-Butanol Pentane 1-Propanol Examples of Class 3 solvents which should be limited by GMP or other quality based requirements.
  • 12. www.julphar.net Solvents for which No Adequate Toxicological Data was Found •The following solvents may also be of interest to manufacturers of excipients, drug substances, or drug products. However, no adequate toxicological data on which to base a PDE was found. •Manufacturers should supply justification for residual levels of these solvents in pharmaceutical products. • Examples : 1,1-Diethoxypropane Methylisopropyl ketone 1,1-Dimethoxymethane Methyltetrahydrofuran 2,2-Dimethoxypropane Petroleum ether Isooctane Trichloroacetic acid Isopropyl ether Trifluoroacetic acid
  • 13. www.julphar.net Options for Describing Limits of Class 2 Solvents These options are used to describe the limit of Class 2 solvents. Testing should be performed for residual solvents when production or purification processes are known to result in the presence of such solvents. Option 1: By assuming a product mass of 10 g administered daily. Concentration (ppm) = 1000 x PDE / Dose Here, PDE is given in terms of mg/day and dose is given in g/day. No further calculation is necessary provided that the daily dose does not exceed 10 g. Option 2: Products that are administered in doses greater than 10 g per day. Applied by adding the amounts of a residual solvent present in each of the components of the drug product. The sum of the amounts of solvent per day should be less than that given by the PDE.
  • 14. www.julphar.net Example for Option 2 The permitted daily exposure to acetonitrile is 4.1 mg per day; thus, the Option 1 limit is 410 ppm. The maximum administered daily mass of a drug product is 5.0 g, and the drug product contains two excipients. The composition of the drug product and the calculated maximum content of residual acetonitrile are given in the following table. Excipient 1 meets the Option 1 limit, but the drug substance, excipient 2, and drug product do not meet the Option 1 limit. however, the product meets the Option 2 limit of 4.1 mg per day and thus conforms to the recommendations in this guideline.
  • 15. www.julphar.net What if the product meets neither the Option 1 nor the Option 2 limit ? The manufacturer could test the drug product to determine if the formulation process reduced the level of acetonitrile. If the level of acetonitrile was not reduced during formulation to the allowed limit, then the manufacturer of the drug product should take other steps to reduce the amount of acetonitrile in the drug product. If all of these steps fail to reduce the level of residual solvent, in exceptional cases the manufacturer could provide a summary of efforts made to reduce the solvent level to meet the guideline value, and provide a risk benefit analysis to support allowing the product to be utilized with residual solvent at a higher level.
  • 16. www.julphar.net Specifications for class 1 and class 2 residual solvents in active substances A) Class 1 solvents used as starting materials They should be routinely controlled, either in a suitable intermediate or in the final active substance. B) Class 1 solvents present as an impurity It should be NMT 30 % of the specified limit, in a suitable intermediate or in the final active substance. Supporting data should be presented on 6 consecutive pilot scale batches or 3 consecutive industrial scale batches. C) Class 2 solvents used in the last step of the synthesis It should be routinely controlled in the final active substance. D) Class 2 solvents used prior to the last step of the synthesis It should be NMT 10 % of the acceptable concentration limit (e.g., acetonitrile 41 ppm). Supporting data should be presented on 6 consecutive pilot scale batches or 3 consecutive industrial scale batches.
  • 17. www.julphar.net Analytical Procedures •Residual solvents are typically determined using chromatographic techniques such as gas chromatography. • Any harmonized procedures for determining levels of residual solvents as described in the pharmacopoeias should be used. • Manufacturers would be free to select the most appropriate validated analytical procedure for a particular application. • If only Class 3 solvents are present, a nonspecific method such as loss on drying may be used.
  • 18. www.julphar.net Reporting levels of residual solvents • Manufacturers of pharmaceutical products need certain information about the content of residual solvents in excipients or drug substances. • The following statements are given in the ICH Guideline as acceptable examples of the information that could be provided from a supplier of excipients or drug substances to a pharmaceutical manufacturer.  Only Class 3 solvents are likely to be present. Loss on drying is less than 0.5%. Only Class 2 solvents X, Y, ... are likely to be present. All are below the Option 1 limit. Only Class 2 solvents X, Y, ... and Class 3 solvents are likely to be present. Residual Class 2 solvents are below the Option 1 limit and residual Class 3 solvents are below 0.5%.
  • 19. www.julphar.net • If Class 1 solvents are likely to be present, they should be identified and quantified. • If solvents of Class 2 or Class 3 are present at greater than their Option 1 limits or 0.5%, respectively, they should be identified and quantified. • Manufacturer could provide a summary of efforts made to reduce the solvent level to meet the guideline value and provide a risk-benefit analysis to support allowing the product to be utilized with residual solvent at a higher level. • Higher levels of residual solvents may be acceptable in certain cases such as short term (30 days or less) or topical application. Justification for these levels should be made on a case by case basis. Example for Residual Solvents Declaration Reporting levels of residual solvents
  • 20. www.julphar.net Residual Solvents in Pharmaceuticals Exposure limits in this guideline are established by referring to methodologies and toxicity data described in EHC and IRIS* monographs. However, some specific assumptions about residual solvents to be used in the synthesis and formulation of pharmaceutical products should be taken into account in establishing exposure limits: 1) Patients (not the general population) use pharmaceuticals to treat their diseases or for prophylaxis to prevent infection or disease. 2) Residual solvents are unavoidable components in pharmaceutical production and will often be a part of drug products. 3) Residual solvents should not exceed recommended levels except in exceptional circumstances. EHC: Environmental Health Criteria IRIS: Integrated Risk Information System
  • 21. www.julphar.net 4) Data from toxicological studies that are used to determine acceptable levels for residual solvents should have been generated using appropriate protocols such as those described for example by FDA Red Book and EPA*. FDA Red Book: Toxicological Principles for the Safety Assessment of Direct Food Additives and Color Additives Used in Food EPA: US Environmental Protection Agency References: Impurities: Guideline for Residual Solvents Q3C(R5) EMA: CVMP/VICH/502/99 Guideline on impurities: residual solvents , Annex I: specifications for class 1 and class 2 residual solvents in active substances
  • 22. www.julphar.net Glossary Term Meaning Term Meaning ICH INTERNATIONAL CONFERENCE ON HARMONISATION LOEL Lowest-Observed Effect Level WHO World Health Organization NOEL No-Observed Effect Level GMP Good Manufacturing Practice PDE Permitted Daily Exposure EHC Environmental Health Criteria TDI Tolerable Daily Intake IRIS Integrated Risk Information System ADI Acceptable Daily Intake IPCS International Program on Chemical Safety USFDA United States Food and Drug Administration USEPA United States Environmental Protection Agency EWG Expert Working Group